Neurobiological and neurocognitive basis of the effects of cannabinoids in animals and man: Therapeutic potential of cannabinoids in psychiatry

Current Pharmaceutical Design

Volumn 20, Issue 13, 2014, Pages 2069-2071

  Bhattacharyya, Sagnik ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CANNABINOID; ENDOCANNABINOID;

ANXIETY DISORDER; COGNITION; DEGENERATIVE DISEASE; DRUG DISCRIMINATION; EDITORIAL; EMOTION; HUMAN; NEUROBIOLOGY; NEUROCHEMISTRY; NEUROIMAGING; NONHUMAN; PLACE PREFERENCE; PRIORITY JOURNAL; REWARD; SCHIZOPHRENIA; STRESS; TREATMENT RESPONSE; ANIMAL; MENTAL DISORDERS;

ANIMALS; CANNABINOIDS; HUMANS; MENTAL DISORDERS;

EID: 84903693448     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161282013140508103821     Document Type: Editorial

References (36)

1. Eggan, S.M.; Lewis, D.A., Immunocytochemical distribution of the cannabinoid CB1 receptor in the primate neocortex: a regional and laminar analysis. Cereb Cortex, 2007, 17, (1), 175-191.
2. Elphick, M.R.; Egertova, M., The neurobiology and evolution of cannabinoid signalling. Philosophical transactions of the Royal Society of London, 2001, 356, (1407), 381-408.
3. Howlett, A.C., The cannabinoid receptors. Prostaglandins & Other Lipid Mediators, 2002, 68-69, 619-631.
4. Pertwee, R.G., The diverse CB1 and CB2 receptor pharmacology of three plant cannabinoids: delta9-tetrahydrocannabinol, cannabidiol and delta9- tetrahydrocannabivarin. British journal of pharmacology, 2008, 153, (2), 199-215.
5. Szabo, B.; Schlicker, E., Effects of cannabinoids on neurotransmission. Handbook of experimental pharmacology, 2005, (168), 327-365.
6. Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; Crippa, J.A.; Kambeitz, J.; Prata, D.; Williams, S.; Brammer, M.; Collier, D.A.; McGuire, P.K., Preliminary report of biological basis of sensitivity to the effects of cannabis on psychosis: AKT1 and DAT1 genotype modulates the effects of delta- 9-tetrahydrocannabinol on midbrain and striatal function. Molecular Psychiatry, 2012, 17, (12), 1152-1155.
7. Bhattacharyya, S.; Crippa, J.A.; Allen, P.; Martin-Santos, R.; Borgwardt, S.; Fusar-Poli, P.; Rubia, K.; Kambeitz, J.; O'Carroll, C.; Seal, M.L.; Giampietro, V.; Brammer, M.; Zuardi, A.W.; Atakan, Z.; McGuire, P.K., Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing. Archives of General Psychiatry, 2012, 69, (1), 27-36.
8. Winton-Brown, T.T.; Allen, P.; Bhattacharyya, S.; Borgwardt, S.J.; Fusar-Poli, P.; Crippa, J.A.; Seal, M.L.; Martin-Santos, R.; Ffytche, D.; Zuardi, A.W.; Atakan, Z.; McGuire, P.K., Modulation of auditory and visual processing by delta-9-tetrahydrocannabinol and cannabidiol: an FMRI study. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology, 2011, 36, (7), 1340-1348.
9. Bhattacharyya, S.; Morrison, P.D.; Fusar-Poli, P.; Martin-Santos, R.; Borgwardt, S.; Winton-Brown, T.; Nosarti, C.; CM, O.C.; Seal, M.; Allen, P.; Mehta, M.A.; Stone, J.M.; Tunstall, N.; Giampietro, V.; Kapur, S.; Murray, R.M.; Zuardi, A.W.; Crippa, J.A.; Atakan, Z.; McGuire, P.K., Opposite effects of delta-9-tetrahydrocannabinol and cannabidiol on human brain function and psychopathology. Neuropsychopharmacology: Official publication of the American College of Neuropsychopharmacology, 2010, 35, (3), 764-774.
10. [10] Bhattacharyya, S.; Fusar-Poli, P.; Borgwardt, S.; Martin-Santos, R.; Nosarti, C.; O'Carroll, C.; Allen, P.; Seal, M.L.; Fletcher, P.C.; Crippa, J.A.; Giampietro, V.; Mechelli, A.; Atakan, Z.; McGuire, P., Modulation of mediotemporal and ventrostriatal function in humans by Delta9- tetrahydrocannabinol: a neural basis for the effects of Cannabis sativa on learning and psychosis. Archives of General Psychiatry, 2009, 66, (4), 442- 451.
11. Fusar-Poli, P.; Crippa, J.A.; Bhattacharyya, S.; Borgwardt, S.J.; Allen, P.; Martin-Santos, R.; Seal, M.; Surguladze, S.A.; O'Carrol, C.; Atakan, Z.; Zuardi, A.W.; McGuire, P.K., Distinct effects of {delta}9-tetrahydrocannabinol and cannabidiol on neural activation during emotional processing. Archives of General Psychiatry, 2009, 66, (1), 95-105.
12. Borgwardt, S.J.; Allen, P.; Bhattacharyya, S.; Fusar-Poli, P.; Crippa, J.A.; Seal, M.L.; Fraccaro, V.; Atakan, Z.; Martin-Santos, R.; O'Carroll, C.; Rubia, K.; McGuire, P.K., Neural basis of Delta-9-tetrahydrocannabinol and cannabidiol: effects during response inhibition. Biological Psychiatry, 2008, 64, (11), 966-973.
13. Atakan, Z.; Bhattacharyya, S.; Allen, P.; Martin-Santos, R.; Crippa, J.A.; Borgwardt, S.J.; Fusar-Poli, P.; Seal, M.; Sallis, H.; Stahl, D.; Zuardi, A.W.; Rubia, K.; McGuire, P., Cannabis affects people differently: inter-subject variation in the psychotogenic effects of Delta9-tetrahydrocannabinol: a functional magnetic resonance imaging study with healthy volunteers. Psychological Medicine, 2013, 43, (6), 1255-1267.
14. Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; Crippa, J.A.; McGuire, P.K., Neural mechanisms for the cannabinoid modulation of cognition and affect in man: a critical review of neuroimaging studies. Current Pharmaceutical Design, 2012, 18, (32), 5045-5054.
15. Bhattacharyya, S.; Crippa, J.A.; Martin-Santos, R.; Winton-Brown, T.; Fusar-Poli, P., Imaging the neural effects of cannabinoids: current status and future opportunities for psychopharmacology. Current Pharmaceutical Design, 2009, 15, (22), 2603-2614.
16. Crippa, J.A.; Derenusson, G.N.; Ferrari, T.B.; Wichert-Ana, L.; Duran, F.L.; Martin-Santos, R.; Simoes, M.V.; Bhattacharyya, S.; Fusar-Poli, P.; Atakan, Z.; Santos Filho, A.; Freitas-Ferrari, M.C.; McGuire, P.K.; Zuardi, A.W.; Busatto, G.F.; Hallak, J.E., Neural basis of anxiolytic effects of cannabidiol (CBD) in generalized social anxiety disorder: a preliminary report. Journal of Psychopharmacology, 2011, 25, (1), 121-130.
17. Martin-Santos, R.; Fagundo, A.B.; Crippa, J.A.; Atakan, Z.; Bhattacharyya, S.; Allen, P.; Fusar-Poli, P.; Borgwardt, S.; Seal, M.; Busatto, G.F.; McGuire, P., Neuroimaging in cannabis use: a systematic review of the literature. Psychological Medicine, 2010, 40, (3), 383-398.
18. Martin-Santos, R.; Crippa, J.A.; Batalla, A.; Bhattacharyya, S.; Atakan, Z.; Borgwardt, S.; Allen, P.; Seal, M.; Langohr, K.; Farre, M.; Zuardi, A.W.; McGuire, P.K., Acute effects of a single, oral dose of d9-tetrahydrocannabinol (THC) and cannabidiol (CBD) administration in healthy volunteers. Current Pharmaceutical Design, 2012, 18, (32), 4966-4979.
19. Stone, J.M.; Morrison, P.D.; Brugger, S.; Nottage, J.; Bhattacharyya, S.; Sumich, A.; Wilson, D.; Tunstall, N.; Feilding, A.; Brenneisen, R.; McGuire, P.; Murray, R.M.; Ffytche, D.H., Communication breakdown: delta-9 tetrahydrocannabinol effects on pre-speech neural coherence. Molecular Psychiatry, 2012, 17, (6), 568-569.
20. Morrison, P.D.; Nottage, J.; Stone, J.M.; Bhattacharyya, S.; Tunstall, N.; Brenneisen, R.; Holt, D.; Wilson, D.; Sumich, A.; McGuire, P.; Murray, R.M.; Kapur, S.; Ffytche, D.H., Disruption of frontal theta coherence by Delta9-tetrahydrocannabinol is associated with positive psychotic symptoms. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology, 2011, 36, (4), 827-836.
21. Bhattacharyya, S.; Sendt, K.V., Neuroimaging evidence for cannabinoid modulation of cognition and affect in man. Frontiers in Behavioral Neuroscience, 2012, 6, 22.
22. Zuardi, A.W.; Crippa, J.A.; Hallak, J.E.; Bhattacharyya, S.; Atakan, Z.; Martin-Santos, R.; McGuire, P.K.; Guimaraes, F.S., A critical review of the antipsychotic effects of cannabidiol: 30 years of a translational investigation. Current Pharmaceutical Design, 2012, 18, (32), 5131-5140.
23. Degenhardt, L.; Hall, W.D.; Lynskey, M.; McGrath, J.; McLaren, J.; Calabria, B.; Whiteford, H.; Vos, T., Should burden of disease estimates include cannabis use as a risk factor for psychosis? PLoS Medicine, 2009, 6, (9), e1000133.
24. Vlachou, S.; Panagis, G., Regulation of Brain Reward by the Endocannabinoid System: A critical review of Behavioral Studies in Animals. Current Pharmaceutical Design, 2014, 20(13), 2072-88.
25. Scherma, M.; Fattore, L.; Castelli, M.P.; Fratta, W.; Fadda, P., The role of the endocannabinoid system in eating disorders: neurochemical and behavioural preclinical evidence. Current Pharmaceutical Design, 2014, 20(13), 2089-99.
26. Castelli, M.P.; Fadda, P.; Casu, A.; Spano, M.S.; Casti, A.; Fratta, W.; Fattore, L., Male and Female Rats Differ in Brain Cannabinoid CB1 Receptor Density and Function and in Behavioural Traits Predisposing To Drug Addiction: Effect of Ovarian Hormones. Current Pharmaceutical Design, 2014, 20(13), 2100-13.
27. Bossong, M.G.; Jager, G.; Bhattacharyya, S.; Allen, P., Acute and non-acute effects of cannabis on human memory function: a critical review of neuroimaging studies Current Pharmaceutical Design, 2014, 20(13), 2114-25.
28. Schoeler, T.; Bhattacharyya, S., The effect of cannabis use on memory function: an update. Substance Abuse and Rehabilitation, 2013, 4, 11-27.
29. Wrege, J.; Schmidt, A.; Walter, A.; Smieskova, R.; Bendfeldt, K.; Radue, E.; Lang, U.; Borgwardt, S., Effects of cannabis on impulsivity: a systematic review of neuroimaging findings. Current Pharmaceutical Design, 2014, 20(13), 2126-37.
30. Lorenzetti, V.; Solowij, N.; Fornito, A.; Lubman, D.; Yucel, M., The association between regular cannabis exposure and alterations of human brain morphology: An updated review of the literature. Current Pharmaceutical Design, 2014, 20(13), 2138-67.
31. Batalla, A.; Crippa, J.A.; Busatto, G.F.; Guimaraes, F.S.; Zuardi, A.W.; Vallverde, O.; Atakan, Z.; McGuire, P.; Bhattacharyya, S.; Martin-Santos, R., Neuroimaging Studies of Acute Effects of THC and CBD in humans and animals: a Systematic Review. Current Pharmaceutical Design, 2014, 20(13), 2168-85.
32. Jacobus, J.; Tapert, S.F., Effects of cannabis on the Adolescent brain Curr Pharm Des, 2014, 20(13), 2186-93.
33. Robson, P.J.; Guy, G.W.; Di Marzo, V., Cannabinoids and schizophrenia: therapeutic prospects. Current Pharmaceutical Design, 2014, 20(13), 2194-2204.
34. Hjorthøj, C.R.; Baker, A.; Fohlmann, A.; Nordentoft, M., Intervention efficacy in trials targeting cannabis use disorders in patients with comorbid psychosis: Systematic review and meta-analysis. Current Pharmaceutical Design, 2014, 20(13), 2205-11.
35. Rabinak, C.A.; Phan, K.L., Cannabinoid modulation of fear extinction brain circuits: A novel target to advance anxiety treatment. Current Pharmaceutical Design, 2014, 20(13), 2212-17.
36. Velayudhan, L.; Diepen, E.V.; Marudkar, M.; Hands, O.; Suribhatla, S.; Prettyman, R.; Murray, J.; Baillon, S.; Bhattacharyya, S., Therapeutic potential of cannabinoids in neurodegenerative disorders: a selective review Current Pharmaceutical Design, 2014, 20(13), 2218-30.